scholarly journals Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression

Hepatology ◽  
2015 ◽  
Vol 61 (3) ◽  
pp. 823-833 ◽  
Author(s):  
Romina Salpini ◽  
Luna Colagrossi ◽  
Maria Concetta Bellocchi ◽  
Matteo Surdo ◽  
Christina Becker ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Immune Escape ◽  
Hepatitis B Surface Antigen ◽  
Virus Reactivation ◽  
Hepatitis B Virus Reactivation ◽  
Genetic Elements ◽  
B Virus

Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier

2008 ◽  
Vol 89 (2) ◽  
pp. 135-138 ◽  
Author(s):  
Paolo Ricchi ◽  
Patrizia Cinque ◽  
Alfonso Lanza Galeota ◽  
Tiziana Di Matola ◽  
Massimiliano Ammirabile ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Combined Therapy ◽  
Virus Reactivation ◽  
Hepatitis B Virus Reactivation ◽  
B Virus

Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study

Lupus ◽  
2017 ◽  
Vol 27 (1) ◽  
pp. 66-75 ◽  
Author(s):  
W T Lin ◽  
Y M Chen ◽  
D Y Chen ◽  
J L Lan ◽  
C S Chang ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Lupus Erythematosus ◽  
Hepatitis B Surface Antigen ◽  
Virus Reactivation ◽  
Systemic Lupus ◽  
Hepatitis B Virus Reactivation ◽  
B Virus

Objective We aimed to investigate risk of hepatitis B virus reactivation in systemic lupus erythematosus patients with different hepatitis B virus infection statuses receiving immunosuppressive therapy. Methods We retrospectively analyzed systemic lupus erythematosus patients with positive hepatitis B surface antigen or anti-hepatitis B core IgG antibody who underwent immunosuppressive therapies from January 2001 to December 2012 at a medical center in Taiwan for evidence of hepatitis B virus reactivation. Results During this period, 906 out of 3125 patients who were diagnosed with systemic lupus erythematosus received screening tests for hepatitis B virus. Thirty-eight patients were identified as hepatitis B surface antigen-positive. Fifteen of 38 (39.5%) hepatitis B surface antigen-positive patients developed hepatitis B virus reactivation, and 53.3% of these patients experienced severe hepatitis flare. Three of 157 hepatitis B surface antigen-negative/anti-hepatitis B core IgG antibody-positive patients (1.9%) experienced hepatitis B surface antigen seroreversion after immunosuppressive therapy. Five patients received prophylactic or preemptive antiviral therapy and none of them developed hepatitis B virus flares. A daily dose of prednisolone greater than 5 mg was a risk factor for hepatitis B reactivation by multivariate logistic analysis. Conclusions The risk of hepatitis B virus reactivation is high in lupus patients receiving immunosuppressive therapy. Antiviral prophylaxis or preemption can effectively reduce the incidence of hepatitis B virus reactivation in lupus patients.

scholarly journals Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report

2019 ◽  
Vol 13 (1) ◽  
Author(s):  
Luca Foroghi Biland ◽  
Ludovica Ferrari ◽  
Vincenzo Malagnino ◽  
Elisabetta Teti ◽  
Carlotta Cerva ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Virus Reactivation ◽  
Virus Surface ◽  
Hepatitis B Virus Reactivation ◽  
B Virus

Abstract Background Although several cases of hepatitis B virus reactivation have been described in patients with a history of hepatitis B virus infection while undergoing treatment for hepatitis C virus infection with direct acting antivirals, the question of whether hepatitis B virus surface antigen immune-escape mutations might play a role has not been addressed so far. Case presentation We report a case of hepatitis B virus reactivation in a Caucasian patient infected with hepatitis C virus during treatment with sofosbuvir and velpatasvir. A 50-year-old man with a genotype 1a hepatitis C virus infection was considered for therapy. His serological profile was hepatitis B virus surface antigen-negative, hepatitis B virus core antibody-positive, hepatitis B virus surface antibody-negative, and anti-hepatitis D virus-positive. The detection of hepatitis B virus deoxyribonucleic acid (DNA) indicated active viral replication during the direct acting antiviral treatment that spontaneously returned to undetectable levels after treatment completion. Starting from week 12 after the end of treatment, hepatitis B virus surface antibody titers and hepatitis B virus e antibody developed. Sequencing analysis revealed the hepatitis B virus genotype D3 and the presence of two relevant immune-escape mutations (P120S and T126I) in the major hydrophilic region by analyzing the S region. Conclusions We speculate that the presence of the hepatitis B virus surface antigen mutations, endowed with the enhanced capability to elude the immune response, could play a role in hepatitis B virus reactivation. This observation confirms that occult hepatitis B infection should also be carefully monitored, through surveillance of the hepatitis B virus viral load before and during direct acting antiviral treatment of hepatitis C virus.

Sign in / Sign up

Export Citation Format

Share Document